NATICK, Mass., Sept. 13, 2011 /PRNewswire/ — Attracting one of
med-tech’s most inspiring leaders, Boston Scientific Corporation
(NYSE:
BSX) has named Michael Mahoney, 46, as President of the
Company, effective October 17, 2011. Mahoney, Worldwide
Chairman of the Medical Device and Diagnostics Group for Johnson
& Johnson, is expected to become Chief Executive Officer (CEO)
of Boston Scientific on November 1, 2012. The transition
period is being implemented to accommodate Mahoney’s
post-employment obligations to Johnson & Johnson, which both
Boston Scientific and Johnson & Johnson have agreed is
appropriate. Ray Elliott, who announced last May that he
would step down as President and CEO, will do so on October 17,
2011. At that time, Hank Kucheman, currently the Executive Vice
President and Group President of the Cardiology, Rhythm and
Vascular (CRV) Group, Boston Scientific’s largest business, will be
promoted to serve as interim CEO until Mahoney assumes the role.
As President, Mahoney will report to Kucheman. In connection
with his promotion to CEO, Kucheman will be appointed to the
Company’s Board of Directors. Elliott will be available to
assist Kucheman and Mahoney through the end of the year, at which
time he will retire, and remain active on the Company’s Board of
Directors.
(Photo: http://photos.prnewswire.com/prnh/20110913/NE67878-a
)
(Photo: http://photos.prnewswire.com/prnh/20110913/NE67878-b
)
Mahoney has more than twenty-two years of healthcare experience
in medical devices, capital equipment and healthcare IT service
businesses with best-in-class companies. He is known as a
driven leader with a proven ability to build strong teams that are
passionate about winning
‘/>”/>
SOURCE